Cargando…

The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis

Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT(1)R)...

Descripción completa

Detalles Bibliográficos
Autores principales: Satapathy, Shakti Ranjan, Ghatak, Souvik, Sjölander, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265834/
https://www.ncbi.nlm.nih.gov/pubmed/37316937
http://dx.doi.org/10.1186/s12964-023-01157-6
_version_ 1785058616035770368
author Satapathy, Shakti Ranjan
Ghatak, Souvik
Sjölander, Anita
author_facet Satapathy, Shakti Ranjan
Ghatak, Souvik
Sjölander, Anita
author_sort Satapathy, Shakti Ranjan
collection PubMed
description Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT(1)R) levels are associated with poor prognosis in CRC patients. Recently, we have revealed the role of the tumor promoter CysLT(1)R in drug resistance and stemness in colon cancer (CC) cells. Here, we show the role of the CysLT(1)R/Wnt/β-catenin signaling axis in the regulation of PD-L1 using both in vitro and in vivo preclinical model systems. Interestingly, we found that both endogenous and IFNγ-induced PD-L1 expression in CC cells is mediated through upregulation of CysLT(1)R, which enhances Wnt/β-catenin signaling. Therapeutic targeting of CysLT(1)R with its antagonist montelukast (Mo), as well as CRISPR/Cas9-mediated or doxycycline-inducible functional absence of CysLT(1)R, negatively regulated PD-L1 expression in CC cells. Interestingly, an anti-PD-L1 neutralizing antibody exhibited stronger effects together with the CysLT(1)R antagonist in cells (Apc(mut) or CTNNB1(mut)) with either endogenous or IFNγ-induced PD-L1 expression. Additionally, mice treated with Mo showed depletion of PD-L1 mRNA and protein. Moreover, in CC cells with combined treatment of a Wnt inhibitor and an anti-PD-L1 antibody was effective only in β-catenin-dependent (APC(mut)) context. Finally, analysis of public dataset showed positive correlations between the PD-L1 and CysLT(1)R mRNA levels. These results elucidate a previously underappreciated CysLT(1)R/Wnt/β-catenin signaling pathway in the context of PD-L1 inhibition in CC, which might be considered for improving the efficacy of anti-PD-L1 therapy in CC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01157-6.
format Online
Article
Text
id pubmed-10265834
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102658342023-06-15 The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis Satapathy, Shakti Ranjan Ghatak, Souvik Sjölander, Anita Cell Commun Signal Research Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT(1)R) levels are associated with poor prognosis in CRC patients. Recently, we have revealed the role of the tumor promoter CysLT(1)R in drug resistance and stemness in colon cancer (CC) cells. Here, we show the role of the CysLT(1)R/Wnt/β-catenin signaling axis in the regulation of PD-L1 using both in vitro and in vivo preclinical model systems. Interestingly, we found that both endogenous and IFNγ-induced PD-L1 expression in CC cells is mediated through upregulation of CysLT(1)R, which enhances Wnt/β-catenin signaling. Therapeutic targeting of CysLT(1)R with its antagonist montelukast (Mo), as well as CRISPR/Cas9-mediated or doxycycline-inducible functional absence of CysLT(1)R, negatively regulated PD-L1 expression in CC cells. Interestingly, an anti-PD-L1 neutralizing antibody exhibited stronger effects together with the CysLT(1)R antagonist in cells (Apc(mut) or CTNNB1(mut)) with either endogenous or IFNγ-induced PD-L1 expression. Additionally, mice treated with Mo showed depletion of PD-L1 mRNA and protein. Moreover, in CC cells with combined treatment of a Wnt inhibitor and an anti-PD-L1 antibody was effective only in β-catenin-dependent (APC(mut)) context. Finally, analysis of public dataset showed positive correlations between the PD-L1 and CysLT(1)R mRNA levels. These results elucidate a previously underappreciated CysLT(1)R/Wnt/β-catenin signaling pathway in the context of PD-L1 inhibition in CC, which might be considered for improving the efficacy of anti-PD-L1 therapy in CC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01157-6. BioMed Central 2023-06-14 /pmc/articles/PMC10265834/ /pubmed/37316937 http://dx.doi.org/10.1186/s12964-023-01157-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Satapathy, Shakti Ranjan
Ghatak, Souvik
Sjölander, Anita
The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
title The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
title_full The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
title_fullStr The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
title_full_unstemmed The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
title_short The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
title_sort tumor promoter cysteinyl leukotriene receptor 1 regulates pd-l1 expression in colon cancer cells via the wnt/β-catenin signaling axis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265834/
https://www.ncbi.nlm.nih.gov/pubmed/37316937
http://dx.doi.org/10.1186/s12964-023-01157-6
work_keys_str_mv AT satapathyshaktiranjan thetumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis
AT ghataksouvik thetumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis
AT sjolanderanita thetumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis
AT satapathyshaktiranjan tumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis
AT ghataksouvik tumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis
AT sjolanderanita tumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis